Lazard Asset Management
ABUS icon

Lazard Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Lazard Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
+23,722
New +$104K ﹤0.01% 1736
2026
Q1 		– Sell
-67,840
Closed -$326K – 1857
2025
Q4 		$326K Buy
+67,840
New +$305K ﹤0.01% 1500
2022
Q4 		– Sell
-23,536
Closed -$44K – 2354
2022
Q3 		$44K Hold
23,536
– – ﹤0.01% 1845
2022
Q2 		$63K Buy
+23,536
New +$60.2K ﹤0.01% 1704

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lazard Asset Management's ABUS Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 23,722 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #1736 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in ABUS as recently as Q4 2025.

Lazard Asset Management first reported a position in ABUS in Q2 2022 and has held it in 4 quarters since. The position peaked at $326K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Lazard Asset Management held 23,722 shares of Arbutus Biopharma worth $114K as of Q2 2026.
  • Arbutus Biopharma was a new Lazard Asset Management position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1736 holding.
  • Lazard Asset Management first reported a position in Arbutus Biopharma in Q2 2022 and has held it in 4 quarters since.
  • Lazard Asset Management's Arbutus Biopharma position peaked at $326K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.